Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Solid Tumor 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × LY2510924 × Clear all
NCT01391130 2019-07-23

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Eli Lilly and Company

Phase 2 Terminated
110 enrolled 14 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Neoplasm Metastasis, Neoplasms

NCT01439568 2019-07-23

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Eli Lilly and Company

Phase 2 Completed
90 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡